Education
About Us
Working with TipRanks
Follow Us
Psyence Biomedical Ltd. (PBM)
:PBM
RESEARCH TOOLSreports
PBM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $108.00
Previous CloseN/A
Volume97.84K
Average Volume (3M)104.88K
Market Cap
$2.49M
Enterprise ValueN/A
Total Cash (Recent Filing)C$128.68K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding4,527,128
10 Day Avg. Volume86,730
30 Day Avg. Volume104,878
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio9.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Psyence Biomedical News
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.31% Mutual Funds
15.16% Other Institutional Investors
84.05% Public Companies and
Individual Investors
PBM FAQ
What was Psyence Biomedical Ltd.’s price range in the past 12 months?
Psyence Biomedical Ltd. lowest stock price was $0.37 and its highest was $108.00 in the past 12 months.
What is Psyence Biomedical Ltd.’s market cap?
Psyence Biomedical Ltd.’s market cap is $2.49M.
When is Psyence Biomedical Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Psyence Biomedical Ltd.’s earnings last quarter?
Currently, no data Available
Is Psyence Biomedical Ltd. overvalued?
According to Wall Street analysts Psyence Biomedical Ltd.’s price is currently Overvalued.
Does Psyence Biomedical Ltd. pay dividends?
Psyence Biomedical Ltd. does not currently pay dividends.
What is Psyence Biomedical Ltd.’s EPS estimate?
Psyence Biomedical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Biomedical Ltd. have?
Psyence Biomedical Ltd. has 4,527,128 shares outstanding.
What happened to Psyence Biomedical Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Biomedical Ltd.?
Currently, no hedge funds are holding shares in PBM
---
Company Description
Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
---
Technical Analysis
TNF Pharmaceuticals
―
Scinai Immunotherapeutics
―
Nucana
―
Protagenic Therapeutics
―
ELEVAI Labs Inc.
―
---